Form 4: Lantheus Holdings Director Heino Sells Shares to Cover Tax Obligations After PSU Vesting

Mary Anne Heino, a director at Lantheus Holdings, sold shares of common stock to cover tax liabilities following the vesting of performance-based restricted stock units (PSUs).

Summary

• Mary Anne Heino, a director at Lantheus Holdings, Inc. (LNTH), reported changes in beneficial ownership of the company's common stock.
• On March 3, 2025, Ms. Heino acquired 50,070 shares of common stock upon the vesting of performance-based restricted stock units (PSUs).
• These PSUs vested at 200% of the target number of shares, resulting in the acquisition.
• Simultaneously, Ms. Heino sold a total of 53,107 shares of common stock in multiple transactions at prices ranging from $91.76 to $96.09 per share.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2024, to cover withholding tax liabilities associated with the vesting of the restricted stock.
• After these transactions, Ms. Heino directly owns 440,399 shares of Lantheus Holdings common stock.
• She also indirectly owns 167,854 shares through a Grantor Retained Annuity Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The vesting of PSUs is positive, but the subsequent sale of shares is a standard practice for tax obligations and doesn't necessarily indicate a negative outlook.

Positives

• The vesting of PSUs indicates that performance targets were met, which could be viewed positively.

Negatives

• The sale of shares, even for tax purposes, could be interpreted negatively by some investors, although it was pre-planned.

Risks

• While the sales were pre-planned, large sales by insiders can sometimes create short-term price volatility.

Future Outlook

The document does not contain any specific forward-looking statements about the company's future performance.

Industry Context

Insider transactions are common and closely monitored in the pharmaceutical industry. Sales to cover tax obligations are a normal part of equity compensation.

Comparison to Industry Standards

• It's common for executives at publicly traded companies, including those in the pharmaceutical sector like Lantheus (LNTH), to utilize Rule 10b5-1 trading plans to manage their stock sales and avoid accusations of insider trading.
• Companies like GE Healthcare, Siemens Healthineers, and Philips Healthcare also have executives who use similar plans.
• The vesting of performance-based restricted stock units (PSUs) is a standard practice in executive compensation across various industries, including pharmaceuticals.
• The vesting percentage of 200% of the target number of shares suggests that Lantheus exceeded its performance goals, which is a positive sign compared to industry peers where PSU vesting might be lower or not achieved at all.

Stakeholder Impact

• The stock sale could have a minor short-term impact on shareholders due to potential price fluctuations.
• The vesting of PSUs rewards management for achieving performance goals, which can positively impact employee morale.

Key Dates